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Summary
Fibrodysplasia ossificans progressiva (FOP) is a severely
disabling, autosomal-dominant disorder of connective
tissue and is characterized by postnatal progressive het-
erotopic ossification of muscle, tendon, ligament, and
fascia and by congenital malformation of the great toes.
To identify the chromosomal location of the FOP gene,
we conducted a genomewide linkage analysis, using four
affected families with a total of 14 informative meioses.
Male-to-male transmission of the FOP phenotype ex-
cluded X-linked inheritance. Highly polymorphic mi-
crosatellite markers covering all human autosomes were
amplified by use of PCR. The FOP phenotype is linked
to markers located in the 4q27-31 region (LOD score
3.10 at recombination fraction 0). Crossover events lo-
calize the putative FOP gene within a 36-cM interval
bordered proximally by D4S1625 and distally by
D4S2417. This interval contains at least one gene in-
volved in the bone morphogenetic protein–signaling
pathway.
Introduction
Fibrodysplasia ossificans progressiva (FOP [MIM
135100]) is a rare, severely disabling, autosomal-dom-
inant disorder characterized by progressive postnatal
heterotopic ossification and by congenital malformation
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of the great toes (fig. 1A and C; Schroeder and Zasloff
1980; Connor and Evans 1982a, 1982b; Connor et al.
1993; Kaplan et al. 1993a, 1998; Smith 1998). Fre-
quently, the first sites of heterotopic bone formation in
children occur within fibroproliferative lesions on the
upper back and neck (fig. 1B). Heterotopic ossification
in patients with FOP occurs in predictable anatomic pat-
terns (Kaplan et al. 1990; Cohen et al. 1993; Rocke et
al. 1994) and leads to extra-articular bony ankylosis of
nearly all joints of the axial and appendicular skeleton
(Connor and Evans 1982a; Cohen et al. 1993; Kaplan
et al. 1993b; Rocke et al. 1994; Shah et al. 1994), which
renders movement impossible (fig. 1C). Death results
most often from complications of severe restrictive–
chest-wall disease (Connor and Evans 1982a; Kussmaul
et al. 1998).
Heterotopic ossification in FOP is induced by minor
injury to the soft tissues but can occur without detectable
trauma (Connor and Evans 1982a; Janoff et al. 1994;
Luchetti et al. 1996; Glaser et al. 1998). The earliest
pathological finding is a perivascular lymphocytic infil-
tration into normal-appearing skeletal muscle (Gannon
et al. 1998). The early and transient inflammatory phase
is followed by muscle-cell degeneration and by highly
vascular fibroproliferative soft-tissue swelling that is in-
distinguishable histologically from aggressive juvenile fi-
bromatosis (Gannon et al. 1998). The fibroproliferative
lesions evolve, through an endochondral process, into
mature lamellar bone with marrow elements (Kaplan et
al. 1993b; Gannon et al. 1998).
Endochondral bone formation during embryogenesis
is first evidenced by the condensation of mesenchymal
cells, followed by the differentiation of these cells into
chondrocytes and, subsequently, by the replacement of
cartilage by bone. Recent investigations have identified
transcription factors—such as Cbfa1 (Ducy et al. 1997;
Komori et al. 1997; Mundlos et al. 1997; Otto et al.
1997) and Sox9 (Bi et al. 1999)—that direct bone and
cartilage formation. Little is known, however, about the
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Figure1 Clinical findings in FOP. A, Radiographs of the feet at age 4 mo in a child with FOP. The soft-tissue shadows clearly outline the
short in-turned great toes due to malformed delta-shaped proximal phalanges (arrowheads), one of the common variations of great-toe mal-
formations seen in FOP. B, Multiple variable-size soft-tissue nodules (preosseous fibroproliferative lesions) on the back of a 4-year-old child
with FOP. These fibroproliferative lesions are frequently the first indication of heterotopic ossification in a child. C and D, Clinical appearance
and skeleton of a man with FOP. The rigid posture in this 25-year-old man was due to ankylosis of the spine, shoulders, and elbows. He died
of pneumonia at age 40 years. Plates and ribbons of ectopic bone contour the skin over the back and arms (C) and can be seen directly on the
skeleton (D). (Courtesy of the Mutter Museum, College of Physicians of Philadelphia; reproduced with permission from Shafritz et al. [1996].)
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signals that initiate the differentiation of cells toward a
chondrogenic or osteogenic pathway. The genetic defect
in FOP is likely to be such an inductive signal.
The molecular cause and pathogenesis of FOP remain
unknown. Overexpression of bone morphogenetic pro-
tein 4 (BMP-4) in immortalized lymphoblastoid cells
(Shafritz et al. 1996; Lanchoney et al. 1998) and in le-
sional fibroproliferative cells (Gannon et al. 1997) has
recently been associated with the condition. The eleva-
tion of steady-state levels of BMP-4 in FOP is due to an
increased rate of BMP-4 transcription (Olmsted et al.
1996). However, BMP-4 expression is not elevated
above normal levels in all cell lines from patients with
FOP (Shafritz et al. 1996; Virdi et al. 1999), and mu-
tations in the BMP-4 gene have not been identified in
patients with FOP (Xu and Shore 1998), indicating that
the molecular cause lies elsewhere, perhaps in a BMP-4
signaling–pathway component that stimulates expres-
sion of the BMP-4 gene or that impairs the action of an
inhibitor.
FOP is a rare condition; the prevalence is ∼0.6/1 mil-
lion live births (Connor and Evans 1982b;Delatycki and
Rogers 1998). Reproductive fitness is low, and most
cases appear to arise by spontaneous mutation (Kaplan
et al. 1993a). The present study describes a genomewide
linkage analysis in four small families containing indi-
viduals affected with FOP and demonstrates locus ho-
mogeneity and linkage of the FOP gene to a 36-cM seg-
ment on the long arm of human chromosome 4.
Subjects and Methods
Subjects
Four small multigenerational families with FOP par-
ticipated in this study (pedigrees are shown in fig. 2):
FOP 1 (Kaplan et al. 1993a), FOP 2 (Connor et al.
1993), and FOP 4 (Janoff et al. 1995) have been de-
scribed elsewhere; FOP 3 is newly documented in the
present report. All participants were evaluated clinically
by one or more of the authors of the present report, and
the FOP status was ascertained before molecular studies
were initiated. Informed consent was obtained in ac-
cordance with the standards set by local institutional
review boards.
Genotyping
Peripheral blood was obtained from the subjects, and,
by use of standard protocols (Sambrook et al. 1989),
genomic DNA was isolated directly either from periph-
eral blood leukocytes or from Epstein-Barr virus–
transformed lymphocyte cell lines. A set of 240 highly
polymorphic microsatellite markers (Human MapPairs
versions 3a and 8a; Research Genetics), spaced25 cM
apart and spanning all human autosomes, were ampli-
fied in four families with FOP (families 1–4 in fig. 2).
For fine mapping, 25 additional markers were identified
from genetic maps of chromosome 4q (by use of the
Research Genetics database) and were amplified. DNA
samples were analyzed by PCR amplification using one
to four primer pairs per reaction. Each reaction con-
tained (in a final volume of 10 ml) 30 ng of genomic
DNA, 10 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2,
0.01% gelatin, 200 mM each dTTP, dGTP, and dATP,
2.5 mM dCTP, 0.35 nCi a-[32P]dCTP, 1.5 mmol of each
primer, and 0.15 U of Taq polymerase (PE Biosystems).
Thermal cycling (Hybaid Omnigene thermal cycler) con-
sisted of 27 cycles of 94C for 30 s, 55C for 75 s, and
72C for 15 s. The amplified PCR products were de-
natured (at 95C for 5 min) and were separated by sized
markers on a 6% polyacrylamide 7.7-M urea gel. The
gels were exposed to autoradiography film (XAR; Ko-
dak) at 70C, with intensifying screens, for 6–48 h.
Autoradiograms were scored independently by at least
two investigators.
Linkage Analysis
Two-point linkage analysis was performed by the
MLINK program by use of data formatted by the Cyrillic
program (Cherwell Scientific). On the basis of clinical
experience with these families, penetrance of the FOP
gene was assumed to be 100%.Multipoint analyseswere
conducted with the GENEHUNTER program (Kruglyak
et al. 1996). Because of the consistent pattern of inher-
itance based on the pedigrees, a single model of a dom-
inant highly penetrant trait was used. The disease-gene
frequency was assigned a value of on the76.0# 10
basis of previous studies. Haplotypes were reconstructed
from the genotype data, by use of the Cyrillic program.
Radiation-Hybrid Mapping
The Massachusetts Institute of Technology (MIT)/
Whitehead Institute GeneBridge 4 radiation-hybrid map
(Whitehead Institute) and National Center for Biotech-
nology Information (NCBI) databases were examined
for previously localized positions of markers and can-
didate genes in the linked region. The positions of some
additional markers and candidate genes were verified by
use of the GeneBridge 4 Radiation Hybrid Panel (Re-
search Genetics). Each 10-ml PCR contained 50 ng of
hybrid template DNA, 50 mM Tris-HCl (pH 8.3), 50
mM KCl, 200 mM each dNTP, 2.5 mM MgCl2, 3 #
MasterAmp Enhancer (Epicenter Technologies), 300
mM each forward and reverse primer, and 0.3 U of
Taq DNA polymerase (Life Technologies). Primers for
SMAD1 were 5′-CTGCTGTCCTTTTGCATTTGGA
(forward) and 5′-TTCATGGTGGC-TCTGAAGATCGG
(reverse). PCR amplification used 36 cycles of 30 s at
94C, 75 s at 58C, and 15 s at 72C, plus a final 6 min
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Figure 3 Combined multipoint LOD scores for the markers in
the 4q27-31 region in four families with FOP. Multipoint LOD scores
were calculated for each of the markers indicated along the X-axis.
The relative genetic distances of these markers, measured (in cM) from
4pter, were derived from the Research Genetics database.
Table 1
Combined Two-Point LOD Scores for FOP and Chromosome 4 Markers
MARKERa
LOD SCORE AT v=
vmax Zmax.00 .05 .10 .15 .20 .25 .30 .35 .40 .45 .50
D4S424 4.3 # 1019 1.16 1.21 1.12 .98 .80 .60 .39 .20 .05 .00 .10 1.21
D4S1625 4.3 # 1019 .16 .07 .17 .21 .23 .22 .18 .14 .08 .00 .25 .23
D4S1586 2.41 2.19 1.95 1.70 1.44 1.17 .88 .59 .32 .11 .00 .00 2.41
D4S1548 3.31 3.00 2.67 2.33 1.96 1.59 1.2 .81 .45 .16 .00 .00 3.31
D4S2934 1.51 1.33 1.15 .97 .78 .60 .43 .27 .13 .03 .00 .00 1.51
D4S1629 1.81 1.63 1.44 1.24 1.04 .82 .61 .39 .20 .05 .00 .00 1.81
D4S2411 2.11 1.91 1.70 1.47 1.24 1.00 .75 .51 .28 .10 .00 .00 2.11
D4S1626 .90 .81 .72 .62 .52 .41 .30 .19 .09 .03 .00 .00 .90
D4S3046 3.01 2.72 2.42 2.10 1.76 1.42 1.07 .72 .41 .15 .00 .00 3.01
D4S2368 .54 .47 .41 .34 .27 .20 .14 .08 .04 .01 .00 .00 .54
D4S1566 2.11 1.91 1.70 1.47 1.24 .99 .73 .48 .24 .07 .00 .00 2.11
D4S2414 2.34 2.12 1.89 1.65 1.39 1.13 .86 .59 .33 .13 .00 .00 2.34
D4S2426 3.31 3.00 2.67 2.33 1.96 1.59 1.20 .81 .45 .16 .00 .00 3.31
D4S1595 2.64 2.36 2.06 1.76 1.44 1.13 .81 .51 .26 .07 .00 .00 2.64
D4S2431 2.71 2.44 2.16 1.87 1.56 1.23 .90 .58 .29 .80 .00 .00 2.71
D4S2637 .16 .21 .30 .31 .28 .23 .17 .10 .05 .01 .00 .15 .31
D4S2417 4.3 # 1019 1.38 1.43 1.31 1.16 .97 .76 .54 .32 .12 .00 .10 1.43
a Order shown is from centromere to telomere.
at 72C, in an MJ Reseach PTC-200. Each reaction was
electrophoresed through 1% agarose gels in TAE buffer
(40 mM Tris-HCl [pH 7.5], 20 mM sodium acetate, 1
mM EDTA). Positive and negative amplification was
scored for all 93 hybrid clones, and the data were sub-
mitted to the GeneBridge 4 mapping service at the
Whitehead Institute.
Results
To identify the chromosomal locus of the FOP gene,
a genomewide linkage analysis using four unrelated fam-
ilies with two or more affected individuals was con-
ducted (fig. 2). In each family, penetrance was com-
plete, and the inheritance pattern was consistent with
autosomal-dominant transmission. Family 1 demon-
strated male-to-male transmission of the FOP pheno-
type, thereby excluding X-linked transmission. Linkage
data from polymorphic microsatellite markers for all au-
tosomes showed that only markers in the 4q27-31 region
segregated with the affected phenotype with no recom-
bination in each of the four families.
Fine mapping of the 4q27-31 region was conducted
with use of additional polymorphic markers within this
interval. The two-point LOD-score calculation for the
combined family data (table 1) produced a maximum
LOD score (Zmax) of 3.31 with D4S1548 and D4S2426
markers at a recombination fraction (v) of 0. Multipoint
analysis resulted in a multipoint Zmax of 3.10 within the
linked interval (fig. 3). Boundaries of the linked region
were established by crossover events for marker
D4S1625 (map position 145 cM) in individual III-4 in
family 3 and for marker D4S2417 (map position 181
cM) in individual III-2 in family 3, placing the putative
FOP gene within a 36-cM interval on the long arm of
human chromosome 4 (fig. 4).
Examination of the 4q27-31 region identified several
plausible FOP candidate genes previously localized
within or near this interval, including SMAD1, IL-15,
15-hydroxyprostaglandin dehydrogenase (PGDH),
LEF1, and a BMP receptor (BMPRIB). To determine
whether these genes are within the linked interval, the
markers at the proximal and distal borders of the linked
region, D4S1625 and D4S2417, were localized on the
Feldman et al.: Linkage of FOP to Chromosome 4q 133
Figure 4 Localization of the FOP-linked interval on the long
arm of human chromosome 4. Schematic representation of the 4q27-
31 region shows some of the markers used in the genetic linkage
analysis. The genetic distances between the markers are indicated and
the cumulative genetic distances (in cM; pter is 0 cM) for the markers
defining the proximal and distal boundaries of the linked interval are
shown in parentheses, under the marker names. Blackened squares
denote regions of allele sharing among affected individuals; open
squares represent recombinant regions. Crossovers in individual III-4
from family 3 identified the proximal boundary, and those in individual
III-2 from family 3 identified the distal boundary.
physical radiation-hybrid map. The Genebridge 4 map
from the Radiation Hybrid Mapping Web site of the
MIT/Whitehead Institute and the NCBI GeneMap 1999
databases were used; unless indicated, cR values refer to
the NCBI map. D4S1625 maps between 615.30 and
618.92 cR (669.6 cR on the MIT/Whitehead Institute
map; 145 cM), whereas D4S2417 was identified at
676.27 cR (739.7 cR on the MIT/Whitehead Institute
map; 181 cM). Radiation-hybrid mapping confirmed
that SMAD1, a leading candidate gene, which encodes
a critical intracellular component of the BMP-signaling
pathway (Hoodless et al. 1996), is located within the
FOP-linked interval of chromosome 4q at 623.30 cR
(675.6 cR on the MIT/Whitehead Institute map; 145
cM), consistent with results reported elsewhere (Lech-
leider et al. 1996). PGDH has been localized close to
the distal border within the linked region, at
671.36–673.33 cR (179 cM), and IL-15 has been
mapped at 615.3 cR (142 cM) near the proximal border.
BMPRIB and LEF1 map outside the linkage region, ac-
cording to the GeneMap 1999 database. Note that ac-
tual ordering of genes is pending verification of radia-
tion-hybrid mapping data.
Discussion
Linkage data from a genomewide screen support the
localization of the gene that causes FOP to 4q27-31, a
36-cM interval on human chromosome 4. No recom-
bination between markers in this region and the FOP
phenotype was observed, and no genetic heterogeneity
was observed in the four families studied, despite pre-
vious observation of clinical and biochemical hetero-
geneity (Janoff et al. 1995; Shafritz et al. 1996; Virdi et
al. 1999). The catastrophic disability of FOP leads to
low reproductive fitness and a paucity of multigenera-
tional families (Connor and Evans 1982b;Delatycki and
Rogers 1998; Kaplan et al. 1998). Although the number
of informative meioses in this study was sufficient to
demonstrate linkage (LOD score 13) of FOP within the
4q27-31 region, additional families that show crossovers
within this region are needed in order to narrow the
target interval before productive positional-cloning ef-
forts can be accomplished, although candidate genes in
the interval can be examined for mutations.
BMP-4, a powerful osteogenic morphogen and a
member of the transforming-growth factor–b superfam-
ily (Wozney et al. 1988; Massague´ 1990; Kingsley 1994;
Hogan 1996a, 1996b), has been proposed as a candidate
gene for FOP (Kaplan et al. 1990), because it is selec-
tively overexpressed in immortalized lymphoblastoid cell
lines and in preosseous fibroproliferative cells from pa-
tients with FOP (Olmsted et al. 1996; Shafritz et al.
1996; Gannon et al. 1997; Lanchoney et al. 1998). Pre-
vious examination of the DNA sequence of the BMP-4
gene alleles of patients with FOP showed no FOP-as-
sociated mutations (Xu and Shore 1998). Furthermore,
the present report excludes linkage of the FOP pheno-
type to chromosome 14, the location of the BMP-4 gene.
However, SMAD1, a BMP pathway–specific gene in-
volved in cytoplasmic and nuclear signal transduction
(Kretzschmar and Massague´ 1998), is located on human
chromosome 4, within the FOP-linked interval and is a
plausible candidate gene for FOP.
Since there are 1100 anonymous transcripts in the
4q27-31–linked interval, the FOP gene may be an as-
yet-undescribed gene in a pathway that influences BMP
activity. However, in addition to SMAD1, several prom-
ising candidate genes in the linkage region warrant con-
sideration. Histopathological examination of lesion bi-
opsies from patients with FOP provides insight into the
pathobiology of FOP and suggests a rationale for con-
sidering other plausible candidate genes within the
linked region. The most prominent feature of an early
FOP lesion is intense perivascular lymphocytic infiltra-
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tion into normal-appearing skeletal muscle, followed by
the appearance of fibroproliferative swellings with in-
tense angiogenesis (Gannon et al. 1998). IL-15 (which
maps near the proximal border of the FOP candidate
region), a cytokine expressed in endothelial cells, has
been shown to initiate angiogenesis and to play a role
in T-cell and B-cell growth and differentiation (Kirman
et al. 1998). NFkB, a transcription factor with a major
role in BMP-4 repression during chick limb develop-
ment, has an activating binding site on the IL-15 pro-
moter (Azimi et al. 1998).
NAD-dependent 15-PGDH is a member of the short-
chain alcohol dehydrogenase enzymes known to catalyze
the reversible inactivation of prostaglandins, powerful
mediators of the inflammatory response (Duax and
Ghosh 1997; Pichaud et al. 1997b). This enzyme has
recently been shown to play a role in vitamin D3–
induced macrophage/osteoclast differentiation (Pichaud
et al. 1997a) and is a plausible candidate gene for FOP,
because of the known osteogenic effects of prostaglan-
dins, specifically PGE-2, and because of the reported
elevation of a PGE-2–like molecule in the serum of pa-
tients with FOP (Levitz et al. 1992).
In summary, we present evidence that the FOP gene
is located on human chromosome 4, within the 4q27-
31 region. The identification of the mutated gene that
causes FOP will illuminate our understanding of the ge-
netic, molecular, and cellular pathways that regulate os-
teoblast-cell differentiation and the de novo formation
of bone and will, in addition, provide a foundation for
development of treatments not only for FOP but also
for the more common disorders of osteogenesis.
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